Last Update 07 Apr 26

Fair value Increased 1.16%

SOBI: Kidney And Sepsis Pipeline Progress Will Shape A More Balanced Outlook

The analyst price target for Swedish Orphan Biovitrum has been raised by SEK 4.90 to SEK 428.50, as analysts reference recent target increases from SEK 395 to SEK 470 and from SEK 470 to SEK 500, alongside updated assumptions for revenue growth, profit margins and future P/E.

Analyst Commentary

Recent research opinions on Swedish Orphan Biovitrum present a mixed picture, with several price target adjustments and rating changes that point to both confidence in the equity story and caution around execution risk.

Bullish Takeaways

Bullish analysts are lifting price targets into a SEK 470 to SEK 500 range, which signals that, based on their assumptions, the current valuation leaves room for upside if the company delivers on revenue and margin expectations.
Target increases are being justified by updated assumptions for revenue growth, profitability and future P/E, suggesting these analysts see the earnings profile as supportive of a higher multiple than previously used.
The upgrade from Underperform to Outperform points to improving confidence in the company’s ability to execute on its plan, which can support both earnings visibility and investor sentiment.
With more than one upward target revision clustered in a short period, bullish analysts appear aligned that the company’s fundamentals and outlook assumptions warrant closer attention from growth oriented investors.

Bearish Takeaways

The downgrade from Buy to Hold indicates that some bearish analysts see the risk or valuation trade off as less attractive at current levels, even with supportive long term assumptions in the sector.
A Hold stance suggests concern that execution on growth and margins may need to catch up with expectations already embedded in recent price targets.
The gap between the highest price target of SEK 500 and more cautious ratings highlights uncertainty around how consistently the company can deliver on the revenue and profit assumptions used in target models.
For readers, the presence of both upgrades and a downgrade is a reminder that, while upside scenarios exist, there are open questions on timing, earnings delivery and how much of this is already reflected in the current share price.

What's in the News

The European Medicines Agency validated Sobi's application to extend the indication for Tryngolza (olezarsen) to adult patients with severe hypertriglyceridemia at or above 880 mg/dL, supported by Phase 3 CORE and CORE2 data in more than 1,000 patients and prior EU approval in familial chylomicronemia syndrome (company announcement).
Topline Phase 2a EMBRACE results for Gamifant (emapalumab) in interferon gamma driven sepsis showed improvement in organ function in 60% of patients on high dose versus 40% on placebo, with 28 day mortality of 40% versus 52% respectively, and a safety profile in line with prior experience (company announcement / ISICEM presentation).
The European Commission approved Aspaveli (pegcetacoplan) for C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis in certain adults and adolescents. The decision was based on Phase 3 VALIANT results that showed benefits across proteinuria, kidney function, and C3 deposit clearance in rare kidney diseases affecting up to 8,000 patients in Europe (company announcement).
Sobi issued earnings guidance for fiscal 2026 and indicated that revenue is anticipated to grow at a low double digit rate at constant exchange rates, giving investors a reference point for company level expectations (company guidance).
Sobi and the Hellenic Institute for the Study of Sepsis plan to advance emapalumab in interferon gamma driven sepsis and discuss next clinical development steps with regulators. Further data disclosure is expected at an upcoming medical conference (company announcement).

Valuation Changes

Fair Value: SEK 423.6 to SEK 428.5, representing a slight uplift in the modeled central value for the shares.
Discount Rate: 5.47% to 5.45%, reflecting a small reduction in the rate applied to future cash flows.
Revenue Growth: 11.87% to 11.94%, indicating a modestly higher assumption for top line expansion in SEK terms.
Net Profit Margin: 22.04% to 22.00%, showing a marginally lower margin assumption, which points to a slightly tighter earnings profile in SEK.
Future P/E: 20.07x to 20.30x, indicating a minor increase in the valuation multiple applied to forward earnings.

9 views

Key Takeaways

Successful Altuvoct launch in Europe and expanding regulatory approvals for Aspaveli and Gamifant could significantly boost revenue through market share growth and new entries.
Strategic operational efficiency, cost management, and increased Beyfortus royalties are expected to enhance margins and stabilize earnings.
Reliance on international expansion and competition challenges may limit revenue growth, while geopolitical and regulatory factors could further impact margins and earnings stability.

Catalysts

About Swedish Orphan Biovitrum

A biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia.What are the underlying business or industry changes driving this perspective?

The successful launch and rapid adoption of Altuvoct in markets like Germany, where it achieved a 57% market share within 9 months, present a significant opportunity for market share growth in Europe, potentially boosting future revenues.
The expected regulatory approvals and market entries for Aspaveli in nephrology indications and Gamifant in secondary HLH show potential for new revenue streams, as these products address unmet medical needs in growing markets.
Expansion of Gamifant into new indications, such as interferon-gamma-driven sepsis and the subsequent international filings, could drive significant long-term revenue growth, solidifying its position in an untapped market segment.
The ongoing development and subsequent potential label expansion of Vonjo through the PACIFICA Phase III study and international launches may unlock new growth areas, positively impacting revenue and earnings.
The strategic focus on enhancing operational efficiency and cost management, alongside anticipated increased royalty rates from Beyfortus, should support margin improvement and earnings stabilization in the coming years.

Swedish Orphan Biovitrum Earnings and Revenue Growth

Swedish Orphan Biovitrum Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Swedish Orphan Biovitrum's revenue will grow by 11.9% annually over the next 3 years.
Analysts assume that profit margins will increase from 1.7% today to 22.0% in 3 years time.
Analysts expect earnings to reach SEK 8.7 billion (and earnings per share of SEK 24.91) by about April 2029, up from SEK 478.0 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as SEK10.3 billion.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 20.3x on those 2029 earnings, down from 289.8x today. This future PE is greater than the current PE for the GB Biotechs industry at 18.2x.
Analysts expect the number of shares outstanding to grow by 0.64% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 5.45%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

The growth rate, while positive, is relatively modest at 3% due to discontinuation of certain manufacturing revenues and seasonal impacts, potentially signaling limited expansion capacity which could affect future revenue expectations.
The reliance on international expansion for products like Altuvoct is subject to reimbursement and regional regulatory challenges, particularly in markets like Spain and France, which could impact revenue growth if expected launches face delays.
The intensified competition in some therapeutic areas, such as the competition Aspaveli faces from new oral medicines, may exert downward pressure on pricing or slow market penetration, affecting net margins and revenue.
Stocking issues and adjustments related to Medicare Part D reform have negatively impacted Vonjo's quarterly performance, highlighting risks that might disrupt earnings consistency if not managed effectively.
Fluctuating exchange rates and potential tariffs due to geopolitical factors could affect both revenue and EBITDA margins, as a significant portion of operations and sales occur in multiple currencies outside of the Swedish krona.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of SEK428.5 for Swedish Orphan Biovitrum based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of SEK500.0, and the most bearish reporting a price target of just SEK308.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be SEK39.6 billion, earnings will come to SEK8.7 billion, and it would be trading on a PE ratio of 20.3x, assuming you use a discount rate of 5.4%.
Given the current share price of SEK400.8, the analyst price target of SEK428.5 is 6.5% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Swedish Orphan Biovitrum?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

SOBI: Upgraded Recommendation Signals Confidence Amid Balanced Risks And Advancing Pipeline